At Texas Retina Associates, we remain committed to conducting ongoing research that will improve care for our patients, and over the past 20 years, our research program has grown to become one of the largest in the country for a community-based practice. We recently opened several new clinical trials:

Choroidal Melanoma

  • DRCR Protocol AL (Lubbock) — A randomized clinical trial evaluating intravitreal faricimab injections or fluocinolone acetonide intravitreal implants vs. observation for prevention of visual acuity loss due to radiation retinopathy.

Diabetic Macular Edema

  • Kirin DME (Fort Worth) — A  Phase II, multi-center, randomized, double-masked, parallel-group study to assess KHK4951, a vascular endothelial growth factor receptor inhibitor, in patients with diabetic macular edema.

Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA)

  • i-SIGHT (Fort Worth) — A microcurrent stimulation therapy for nonexudative age-related macular degeneration (AMD).

Wet Macular Degeneration

  • Burgundy (Arlington, Dallas Main) — A three-part study to investigate zifibancimig following intravitreal administration of multiple ascending doses and continuous delivery from the port delivery in patients with neovascular age-related macular degeneration (AMD).
  • DRCR Protocol AO (Lubbock) — Home OCT-guided treatment versus treat and extend for the management of neovascular age-related macular degeneration (AMD).
  • Kirin AMD (Fort Worth) — A Phase II, multi-center, randomized, double-masked, parallel-group study to assess KHK4951, a vascular endothelial growth factor receptor inhibitor, in patients with neovascular age-related macular degeneration (AMD).
  • NORSE 8 (Dallas Main) — ONS-5010 compared to Lucentis in subjects with neovascular age-related macular degeneration (AMD).

Altogether we currently have 34 open studies, offering access to promising new treatments for choroidal melanoma, diabetic macular edema, diabetic retinopathy, dry macular degeneration with geographic atrophy, retinal vein occlusion, wet macular degeneration, and uveitis.

Click here to view our current, actively enrolling clinical trials.

For more information or to determine your eligibility for any of these studies, please contact our research department at (214) 692-6885, ext. 1.